Wed, Sep 22, 2:15 PM - 3:30 PM
Virtual
Clinical and Statistical Perspectives on Post-ICH E9 (R1) Addendum Estimand Use: Current Status and Future Directions
Panel Discussion (303542)
*
Sylva Collins, FDA/CDER/OTS
*
David Lebwohl, Intellia Therapeutics
*
Bohdana Ratitch, Bayer
*
John Scott, US Food and Drug Administration
